Study: Use of modern obesity treatments "safe for psychiatric patients"

An extensive overview of scientific evidence has revealed that new obesity medicine, known as “total of Glucagon-1 peptide-1” peptide receptors “, is safe and effective for patients with mental disorders as it helps them to lose weight and improve the control of blood sugar levels, without increasing the risk of suicide or psychological. Obesity at a rate of more than three times the general population, and this risk is partly related to the effects of the side of the psychological drugs, such as antidepressants and psychopathic, causing a significant increase in weight. is more likely to develop obesity, type 2 diabetes, blood fat disorders and even heart disease, and obesity rate between this reaches 60%, that is, it is three times more than the general population. Psychotherapy “is not a picnic” and the researchers say that psychotherapy “is not always a picnic” as much antipsychotics, especially from the second generation such as “Holnazabin” and “Clozapin”, contributes to weight gain and the increase of sugar levels and cholesterol in the blood. This effect is not limited to antipsychotics. On the contrary, some antidepressants such as “Mertzabin” and “amitripelin” have a similar effect, and here doctors and patients fall into a dilemma: treat them despite the physical side effects, or seek alternative solutions? This height is due to crashing factors that include hormonal and behavioral changes as a result of the disease itself, and the side effects of psychological drugs such as antipsychotics and antidepressants affecting appetite and metabolism, in addition to the lack of physical activity; Due to social isolation or the decrease in motivation, which makes the handling of obesity in this category a double challenge; Since traditional options such as diets and exercise under these circumstances may not be possible or always effective. In light of this dilemma, a new group of medicines that can represent a lifeline has appeared; New obesity medication. This medication was originally used to treat type 2 diabetes, stimulate insulin secretion, reduce glucagon and slow down the stomach, reduce appetite and lead to weight loss. However, the surprise was also in the great effectiveness of losing weight, even in non -diabetes, who urged the US food and drug administration to agree to use it to treat obesity. The drug containing the active substance “simaglotide” is unanimously the best in this group, thanks to the improved composition. Studies have shown that it excels in the “lyragloid” medication in weight loss, and the weight loss rate was 15.8% compared to only 6.4% with lyragloid, and simaglotide has a better economic effectiveness, and its possibility is less due to its side effects. The review contains 36 previous studies from 19 countries, covering the data of more than 25 thousand adults, and the results have shown that the use of this medicine has led to a noticeable weight loss and improvement in sugar levels, even among those who take heavy psychiatry. For example, the participants with schizophrenia who consumed “Lyraglotide” showed a decrease in their weight at a rate of 5.3 kg, and an improvement in sugar indicators within six months, compared to those who took imaginary therapy. In terms of using ‘Simajlotide’, in 68 weeks it led to reducing weight by 15.7% in patients taking antidepressants. Obesity medication and suicide rate, although most importantly, is the absence of any relationship between this medication and an increase in suicide ideas or behavior. Six studies have shown that patients who used new weight loss medicine did not have an increase in suicide rates or entered psychiatric clinics. The review revealed that this medicine could also improve mental health. In five studies, it was observed in the mood and the quality of life in patients with chronic psychological disorders, and other studies recorded an improvement in a general sense of mental health and the quality of life in people who are not infected with mental disorders after using the medicine themselves. The researchers note that these effects are due to the properties of anti -inflammatory and oxidants, which contribute to reducing nervous system infections; It is one of the theories offered to understand some mental disorders. Despite the positive results, the researchers ask to deal with this medication, especially in the early stages of treatment, because it emphasizes the need to perform longer and more comprehensive studies to determine the effectiveness and safety of this medicine in the long run, including the possibility of using it as direct treatments for some mental illnesses in the future.